AbbVie, Genmab say epcoritamab plus R-CHOP cuts risk of progression or death 51% in Phase 3 DLBCL trial
ABBV•AbbVie and Genmab said epcoritamab plus R-CHOP cut the risk of disease progression or death by 51% in a Phase 3 trial for newly diagnosed diffuse large B-cell lymphoma. The regimen remains investigational in this setting.
1. Trial results
The companies reported positive topline Phase 3 results for epcoritamab combined with R-CHOP in newly diagnosed diffuse large B-cell lymphoma, with a 51% reduction in the risk of progression or death versus standard R-CHOP. Safety was broadly consistent with the known profiles of the individual medicines, with no new concerns highlighted. The results have not yet been presented; the companies plan to submit the data to a future medical meeting, and AbbVie plans to engage regulators globally on next steps.
